Get started
Author

Alix Devaux

Observed names: A. Devaux, Devaux, Alix
ORCID: 0009-0000-0320-1850
Observed ORCID: 0009-0000-0320-1850
OpenAlex ID: A5019931969
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
2025 · Alexander B Olawaiye, Laurence Gladieff, et al. · The Lancet · 76
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
2026 · Domenica Lorusso, Laurence Gladieff, et al. · The Lancet · 34
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
2024 · Alexander B. Olawaiye, Jae-Weon Kim, et al. · Journal of Gynecologic Oncology · 12
PDF
GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors
2025 · Pierre Van Meerbeeck, Douae Maatougui, et al. · Cancer Immunology Immunotherapy · 8
ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).
2025 · Alexander Olawaiye, Laurence Gladieff, et al. · Journal of Clinical Oncology · 5
PDF
Management of metastatic melanoma with new immunotherapy approaches beyond PD-1/CTLA-4 inhibitors
2022 · Alix Devaux, Jean-Francois Baurain · Current Opinion in Oncology · 4
70O Phase III results of relacorilant + nab-paclitaxel vs nab-paclitaxel in platinum-resistant ovarian cancer (PROC) (ROSELLA, GOG-3073, ENGOT-ov72): Secondary endpoints
2025 · D. Lorusso, L. Gladieff, et al. · ESMO Open · 3
PDF
#205 ROSELLA (GOG-3073, ENGOT-Ov72/MITO): a phase 3 study of relacorilant + nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer
2023 · Domenica Lorusso, Andrea Bagameri, et al. · International Journal of Gynecological Cancer · 3
PDF
Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer
2025 · Alix Devaux, Gabriela Beniuga, et al. · Breast Cancer Research · 2
PDF
Abstract P4-07-16: B-IMMUNE final analysis: a phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers
2023 · Alix Devaux, Gabriela Beniuga, et al. · Cancer Research · 2
TP019/#1387 Rosella (GOG-3073, ENGOT-OV72/MITO): a phase 3 study of relacorilant + nab paclitaxel vs. nab-paclitaxel in platinum-resistant ovarian cancer
2023 · Domenica Lorusso, Andrea Bagameri, et al. · International Journal of Gynecological Cancer · 1
PDF
Abstract P2-14-12: B-immune interim analysis: A phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers
2022 · Javier Carrasco, Claire Quaghebeur, et al. · Cancer Research · 1
A phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)
2018 · A. Devaux, J.-L. Canon, et al. · Annals of Oncology · 1
Phase 3 Rosella (gog-3073, Engot-ov72) Trial of Relacorilant + Nab-paclitaxel Vs Nab-paclitaxel in Platinum-resistant Ovarian Cancer: Primary Results and Outcomes in Older Patients
2025 · Alexander Olawaiye, Laurence Gladieff, et al. · International Journal of Gynecological Cancer
Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
2025 · Alexander B. Olawaiye, Laurence Gladieff, et al. · Obstetrical & Gynecological Survey
178P Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy/immunotherapy
2023 · C. Birchall, A. Merhi, et al. · Immuno-Oncology Technology
PDF
Abstract PS17-21: Characterization of the immune microenvironment in ductal carcinoma in situ of the breast
2021 · Soizic Garaud, Alix Devaux, et al. · Cancer Research
Works count: 18
Citation count: 152
H-index: 5
I10-index: 3
Year
Topic
Type